Get the latest on MHICC through recent headlines, feature stories and news. Stay up-to-date on the latest news and information from MHICC.

Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
November 27, 2023

Dr. Jean-Claude Tardif, the principal investigator of the study and Director of the Research Center at the Montreal Heart Institute stated, "We are excited to explore the potential therapeutic benefits of avenanthramides and believe results from this study could mark a significant step forward in understanding the potential of avenanthramides in cardiovascular disease. Not only will the study assess safety of avenanthramides in healthy subjects, but it could also provide early signs of activity in subjects with low grade inflammation as part of the Phase 2a component. The results of such studies will provide valuable insights into the potential role of avenanthramides in reducing vascular inflammation and may have implications for cardiovascular health.”

Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
December 22, 2022

Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has received approval from Health Canada to initiate its Phase 1/2a study evaluating the safety, tolerability, bioavailabilty and efficacy of its pharmaceutical grade tablet of avenanthramide as a potential anti-inflammatory product.

The Montreal Heart Institute Receives $9.35 Million From the Quebec Government to Lead a Major Virtual Clinical Trial Project
December 13, 2021

The Montreal Heart Institute (MHI) announces that it has won a request for proposals from the Fonds d’accélération des collaborations en santé (FACS). Pierre Fitzgibbon, Minister of Economic and Innovation, announced today a $9.35 million grant from the Government of Quebec to develop and deploy the project entitled Paradigm Shift in the Conduct of Clinical Trials...

Fighting gut infections contributes to preventing Crohn’s disease and ulcerative colitis.
November 11, 2021

A research team from the Montreal Heart Institute (ICM) has shown that genes present in specific intestinal cells protect against the development of inflammatory bowel diseases (IBD). Published today in the scientific journal Genome Medicine, the study results show that more than a dozen of these genes, which contribute to the development of Crohn’s disease and ulcerative colitis, help fight viral and bacterial infections ...

A new world-class hub for clinical research and precision medicine
October 26, 2021

Reaching nearly $17.5 million, this initiative launched as part of the first FACS program call for proposals is supported by the Ministry of Economy and Innovation (MEI) with a $6.45 million grant and is co-funded by private partners, including Quebec-based DalCor Pharmaceuticals, world-class biopharmas AstraZeneca, Bayer Inc. et Pharmascience as well as the Montreal Heart Institute Foundation...